Harnessing anticalin technology as a multi-targeted treament approach for vision loss

糖尿病是世界范围内导致视力丧失和失明的主要原因，它是由两种名为血管内皮生长因子和血管紧张素转换酶2的因素引起的，这两种因素会损害血管。目前的治疗方法只阻断血管内皮生长因子，许多患者没有反应，对视力造成不可逆转的损害。我们使用突破性的抗血管紧张素转换酶技术制造了一种新药(PRS-AUS1)，可以同时阻断血管内皮生长因子和血管紧张素转换酶2。研究将在动物模型中进行，并转移到患者身上，在这些患者中，我们预计与目前的治疗相比，结果会有所改善。

Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.